First pediatric patients treated with ProTrans in type-1 diabetes phase II study

December 21, 2022

NextCell Pharma AB ("NextCell") supports the pediatric diabetes clinical trial conducted at Uppsala University Hospital by Principal Investigator Professor Per-Ola Carlsson with the stromal cell treatment, ProTrans. At the end of October 2022, the Data Safety and Monitoring Board recommended that phase II part of this pivotal trial should be initiated. Now the first two adolescents in the older age cohort (12-21 years) have received treatment.
‍

Recruitment of children and adolescents newly diagnosed with type-1 diabetes is underway. Patients who can participate in the study must be between 12 and 21 years of age and should have received their diagnosis in the last 6 months. Two out of a total of 30 patients have now received treatment with either ProTrans or placebo.

"The study is progressing according to plan; I have a fantastic study team. The children, and not least their parents, are knowledgeable and very interested, which is inspiring," says Professor Per-Ola Carlsson.

The first part of ProTrans-Young is a safety study (phase I) where all patients have been treated at Uppsala University Hospital. Three patients aged 12-18 years first received treatment, followed by 3 patients aged 7-11 years. Safety data was reviewed by the Data Safety and Monitoring Board after all 6 patients were evaluated at the 3-month follow-up visit. The Board recommended that the study should continue with the second part, which is a randomized and placebo-controlled (phase II) study including a total of 60 children and adolescents with type-1 diabetes, 30 of whom will be treated with ProTrans and 30 with placebo. Initially, 30 patients aged 12-21 will be treated. We can now report that the first two patients have now received treatment. After treatment and 6-month follow-up of the entire age group, the Data Safety and Monitoring Board will again review the safety data before continuing to treat the remaining 30 patients aged 7-11.

The Principal Investigator is Professor Per-Ola Carlsson, Uppsala University and Uppsala University Hospital with co-investigators Professor Helena Elding Larsson, Skåne University Hospital and Professor Johnny Ludvigsson, Linköping University Hospital. The Data Safety and Monitoring Board consists of chairman Professor Ulf Smith, Sahlgrenska, Professor Mikael Rydén, Karolinska Institutet and Professor Anders Fasth, Queen Silvia’s Children's Hospital.

Uppsala University Hospital is the sponsor of the study, which is funded by third-party research grants. NextCell contributes ProTrans and placebo to the study. In addition, the company will support the trial with logistics, documentation and expert competence. No additional monetary compensation will be made.

The full title of the study is: "A Double-blinded, Randomized, Parallel, Placebo-controlled trial of Wharton's Jelly-derived Allogeneic Mesenchymal Stromal Cells to treat Type I Diabetes in Children and Adolescents"(EudraCT 2020-004520-42).

About ProTrans:

ProTrans is NextCell's first drug candidate based on their patent pending selection algorithm. It is an allogeneic cell therapy which means that donated cells, not the patient's own, are used. The cells are extracted from donated umbilical cord tissue and the cells are then expanded to generate large, therapeutic doses of drug product.

ProTransis defined by the selection algorithm, a method for selecting cells with suitable immunomodulatory effect that is assessed in a panel of different analyzes. The algorithm makes an overall assessment of several functional analyzes to identify optimal donors and cells for the manufacture of cell therapies. NextCell’s advanced selection method has a scalable ability and guarantees high reproducibility and efficacy compared to other applications in cell therapy. The careful selection method results in cells of consistently high quality and a strong safety profile with few side effects.

For more information about NextCell Pharma AB, please contact:

Mathias Svahn, CEO

Patrik Fagerholm, CFO

Tel: +46 8-735 5595

E-mail: info@nextcellpharma.com

Webpage: www.nextcellpharma.com

LinkedIn: https://www.linkedin.com/company/15255207/

Twitter: https://twitter.com/NextCellPharma

Certified Adviser

‍‍FNCA Sweden AB is assigned as Certified Adviser, 08-528 00 399, info@fnca.se.

About NextCell Pharma AB

NextCell is a cell therapy company in clinical phase II. The company has developed a proprietary and patented platform technology to produce mesenchymal stromal cells adapted for allogeneic treatment of various autoimmune and immunological diseases. The drug candidate ProTrans is now being tested for the treatment of type-1 diabetes as well as respiratory complications caused by Sars-CoV-2 infection. The focus is to take ProTrans to market approval for type-1 diabetes via a phase III study. ProTrans is evaluated in two clinical COVID-19 studies, in Sweden and Canada. NextCell is working on completing its own GMP facility for the manufacture of ProTrans. The GMP facility is expected to be ready for manufacturing smaller quantities of ProTrans in 2023. NextCell also owns 8.5% of FamicordTX, a start-up company in CAR-T and oncology, and 100%of Cellaviva, Scandinavia's largest stem cell bank for family savings of stem cells from umbilical cord blood and umbilical cord tissue with permission from the Swedish Health and Social Care Inspectorate (IVO).

‍

Download attachment Read full press release on Cision (external link)

2026-03-03

NextCell Pharma presents historical quarterly figures

At the Extraordinary General Meeting of NextCell Pharma AB (publ) (“NextCell” or the “Company”) held on 21 August 2025, it was resolved that the Company shall change its financial year from a broken financial year September–August to a calendar year January–December. The Company’s first full financial year in accordance with the calendar year will be 2026. To facilitate historical comparisons and enhance transparency for future reports that will follow the calendar year structure, the Company is today publishing financial information for the five most recent comparative quarters.

Read more Read more

2026-02-26

NextCell publishes Year-End Report 2024/2025

NextCell Pharma AB (publ) (“NextCell” or the “Company”) publishes its Year-End Report for the extended financial year September 1, 2024 – December 31, 2025. The report is available on the company´s website: www.nextcellpharma.com. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period last year for the fourth quarter (October-December 2024) and twelve months (the previous fiscal year September 2023 - August 2024).

Read more Read more

2026-02-17

NextCell Participating in JETRO’s Japan Entry Acceleration Program

NextCell Pharma AB (“NextCell” or the “Company”) announces its participation in the Japan Entry Acceleration Program (“JEAP”) in regenerative medicine, an international accelerator initiative organized and funded by JETRO. NextCell is communicating its participation in connection with the Company’s current presence in Tokyo, where program activities and meetings with Japanese industrial, regulatory and financial stakeholders are now taking place.

Read more Read more

2026-02-03

Seven-year follow-up data from ProTrans-Repeat demonstrate sustained disease-modifying effects of ProTrans in type 1 diabetes

NextCell Pharma AB (“NextCell” or the “Company”) today announces long-term follow-up data from the ProTrans-Repeat study showing sustained preservation of endogenous insulin production in patients with newly diagnosed type 1 diabetes. The data extends to approximately 6 years after the last ProTrans infusion, corresponding to 7 to 7.5 years since the first infusion.

Read more Read more

2026-01-21

NextCell provides strategic update on focused market progression, highlighting Hong Kong as gateway to the Chinese market

NextCell Pharma AB (“NextCell” or the “Company”) provides a strategic update on its focused market progression strategy, aimed at accelerating value creation by advancing ProTrans™ in adult patients, where NextCell already has a strong clinical foundation, while simultaneously strengthening the company’s global partnering position. This approach builds on NextCell’s original development strategy and is designed to create multiple independent value drivers for the company.

Read more Read more

2026-01-21

NOTICE OF EXTRAORDINARY GENERAL MEETING IN NEXTCELL PHARMA AB (PUBL)

The shareholders of NextCell Pharma AB (publ), reg. no. 556965-8361, (the "Company") are hereby invited to attend an extraordinary general meeting on Tuesday, 10th of February 2026, at 10:00 CET at Novum-huset, floor 6 (lift E), Hälsovägen 7, Huddinge. Registration for the meeting will commence at 09.30 CET.

Read more Read more

2026-01-21

NextCell decides to propose a directed share issue of SEK 15 million

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, NEW ZEALAND, RUSSIA, SINGAPORE, HONG KONG, JAPAN, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO “IMPORTANT INFORMATION” AT THE END OF THE PRESS RELEASE. The Board of Directors of NextCell Pharma AB (“NextCell” or the “Company”) has resolved to propose to the extraordinary general meeting (the “Extraordinary General Meeting”) to resolve on a directed share issue comprising a total of 15,000,000 shares to a number of strategic investors at a subscription price of SEK 1.00 per share (the “Directed Issue”). Participating investors include both new investors and a number of larger existing shareholders. The Extraordinary General Meeting is planned to be held on Tuesday, 10 February 2026. Notice of the Extraordinary General Meeting will be announced separately.

Read more Read more

2026-01-15

Six-year data demonstrate a durable disease-modifying effect of ProTrans in type 1 diabetes

NextCell Pharma AB (“NextCell” or the “Company”) today announces that six-year follow-up data indicate that a single infusion of ProTrans provides a long-lasting and clinically relevant preservation of endogenous insulin production in patients with newly-diagnosed type 1 diabetes. Patients treated with ProTrans continue to exhibit clinically relevant levels of stimulated C-peptide well beyond expected levels as seen with the natural course of the disease.

Read more Read more